Skip to content
Shagandha®
  • About Shagandha®
    • Introduction
    • Traditional Significance
    • Chemistry
    • Why Shagandha®?
      • Complies with USP monograph
      • NON-GMO Project Verified
    • Benefits
  • Research
    • Preclinical
    • Clinical
    • Publications
  • IP Rights
    • Patents
    • Trademark Licence
  • About Sabinsa
    • Newsroom
      • Press Releases
      • Shagandha® Book
      • Ads
      • FAQs
  • Contact Us

Sabinsa receives “No Questions” letter from US FDA on GRAS Status for LactoSpore®

Sabinsa Corporation has hit another important milestone for the shelf-stable probiotic LactoSpore® with receipt of a “no questions” letter on Generally Recognized As Safe (GRAS) status from the US FDA.

“Hearing from FDA that ‘the agency has no questions at this time regarding Sabinsa Corporation’s conclusion that B. coagulans spore preparation is GRAS under the intended conditions of use’ underscores Sabinsa’s commitment to demonstrating the safety of LactoSpore®,” said Dr. Muhammed Majeed, founder of Sabinsa.

Soni & Associates (Vero Beach, Florida) worked with Sabinsa on LactoSpore®’s self-affirmed GRAS status in 2009 and again on this next important step.

While many manufacturers of functional foods are comfortable enough with self-affirmed GRAS status to have included LactoSpore® in a variety of foods and beverages ranging from baked goods to milk products, jams & jellies, gelatins & puddings, soups, snacks, candy, sugar, non-alcoholic beverages and even instant tea and coffee, having the FDA’s notification that they have reviewed information on LactoSpore® and have no questions about the product’s safety opens many more doors. In any and all food categories, a maximum level of approximately 2×109 colony forming units per serving (cfu/serv) is generally recognized as safe.

“This is yet another accolade for Sabinsa’s probiotic and our support for this ingredient from its use in pharma, in dietary supplements, in cosmetics, and now more than ever, in functional foods,” said Shaheen Majeed, Sabinsa’s Marketing Director. “I commend our scientists for this achievement, as well as the production team at our dedicated world-class probiotic factory in India for producing this fine probiotic.”

LactoSpore® was cleared by Health Canada as approved for sale in that country in January 2015, and has recently been the subject of several recently published clinical studies.

Back

About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

 

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com

Global Contact List

USAIndia
Utah, USAJapan
AustraliaPoland
BrasilKorea
CanadaSouth Africa
ChinaVietnam
Germany 

Contact us

    © 2025 Sabinsa. All Rights Reserved | Privacy Policy | Sitemap | Terms of Use | Disclaimer

    ×

    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.